Xichen Lin

This inventor holds 25 USPTO granted patents and 22 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Gasherbrum Bio, Inc., Glaxo Group Limited, Glaxosmithkline Intellectual Property Development Limited. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xichen Lin. Retrieved from https://idiyas.com/inventor/xichen-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 22)

% Patents Active = 44.0

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 27)

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 26(Granted Patents)

Location History:

King of Prussia, PA (US) (2009 - 2013)
Shanghai, CN (2012 - 2024)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

Smithkline Beecham Corporation

patents

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

GLP-1 Agonists

CXCR2 Inhibitors

ROR-gamma Modulators

p38 Kinase Inhibitors

Heterocyclic Compounds

Indole Carboxamides

Chemical Compounds

Heteroaryl Compounds

Oxadiazole Indole Compounds

Cyclopentene Derivatives

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595264 - Heterocyclic GLP-1 agonists (2026-04-07),

2. 12552791 - Heterocyclic GLP-1 agonists (2026-02-17),

3. 12528781 - Heterocyclic GLP-1 agonists (2026-01-20),

4. 12221442 - Heterocyclic GLP-1 agonists (2025-02-11),

5. 11926643 - Heterocyclic GLP-1 agonists (2024-03-12),

6. 11926626 - Heterocyclic GLP-1 agonists (2024-03-12),

7. 11897851 - Heterocyclic GLP-1 agonists (2024-02-13),

8. 11492365 - Heterocyclic GLP-1 agonists (2022-11-08),

9. 10336719 - 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors (2019-07-02),

10. 10106515 - 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors (2018-10-23),

11. 10005731 - Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases (2018-06-26),

12. 9902735 - Heteroaryl substituted compounds as RORγ inhibitors (2018-02-27),

13. 9902715 - Compounds (2018-02-27),

14. 9868724 - Compounds (2018-01-16),

15. 8389508 - Heterocyclic compounds (2013-03-05),

Title: Xichen Lin: Innovator in GLP-1 Agonists from Shanghai

Introduction

Xichen Lin is an accomplished inventor based in Shanghai, China, with an impressive portfolio of 22 patents. His work primarily focuses on the development of heterocyclic GLP-1 agonists, which are pivotal in the pharmaceutical landscape for their potential in treating metabolic disorders.

Latest Patents

Among his latest patents, Xichen Lin has made significant contributions with disclosures related to heterocyclic GLP-1 agonists. These innovations encompass formulas including pharmaceutically acceptable salts and solvates, alongside pharmaceutical compositions containing the same. His research in this area showcases his commitment to advancing medical treatments and improving patient outcomes.

Career Highlights

Throughout his career, Xichen Lin has worked with prestigious organizations, such as Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His tenure in these companies has allowed him to gain practical experience in the realm of patent development and innovation.

Collaborations

In his professional journey, Xichen Lin has collaborated with talented individuals, including Hui Lei and James Francis Callahan. These partnerships have fostered a creative environment, contributing to the successful development of various patents that aim to enhance therapeutic approaches in medicine.

Conclusion

Xichen Lin’s dedication to innovation and his substantial patent portfolio highlight his impact in the field of pharmaceutical research. His work on GLP-1 agonists represents a vital advancement in the development of new treatments. As he continues to pursue groundbreaking inventions, the medical community looks forward to the potential benefits of his contributions.

Profile summary based on public USPTO records.